Intercept Pharmaceuticals (NASDAQ:ICPT) is developing a first-in-class drug, obeticholic acid (OCA) that modulates bile production to reduce liver stress. Because OCA is a first-in-class drug targeting an orphan disease known as primary biliary cirrhosis (PBC) and appears to be safe and effective, OCA has a high probability of FDA approval. The long-term strategy of ICPT is promising: Piggybacking on the natural properties and bioactivity of bile acids will open doors for ICPT in large chronic disease markets that include metabolic disorders (diabetes/obesity) and heart disease. ICPT's market cap ($1B) is on par with other companies in a similar situation. I am waiting to see the Phase III clinical trial results this quarter and early in 2014 before...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|